Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 December 2022 - 08:00AM
Business Wire
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical
company developing STAR-0215 for the treatment of hereditary
angioedema and focused on life-changing therapies for rare and
niche allergic and immunological diseases, granted stock options to
purchase 1,000 shares of Astria’s common stock on December 1, 2022
under Astria’s 2022 Inducement Stock Incentive Plan. The 2022
Inducement Stock Incentive Plan is used exclusively for the grant
of equity awards to individuals who were not previously an employee
of Astria.
The options were granted as an inducement material to an
employee or employees entering into employment with Astria in
accordance with Nasdaq Listing Rule 5635(c)(4). The options have an
exercise price of $11.00, which is equal to the closing price of
Astria’s common stock on December 1, 2022 (the “Grant Date”), and
will vest over a four-year period, with 25% of shares vesting on
the first anniversary of the employee’s employment start date
(which preceded the Grant Date) and the remaining shares vesting
monthly on a ratable basis over the following 36 months, subject to
the employee’s continued employment with Astria on such vesting
dates. The options are subject to the terms and conditions of the
2022 Inducement Stock Incentive Plan and the terms and conditions
of an award agreement covering the grant.
About Astria Therapeutics: Astria Therapeutics is a
biopharmaceutical company, and our mission is to bring
life-changing therapies to patients and families affected by rare
and niche allergic and immunological diseases. Our lead program,
STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein
in clinical development for the treatment of hereditary angioedema.
Learn more about our company on our website, www.astriatx.com, or
follow us on Twitter and Instagram @AstriaTx and on Facebook and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221202005322/en/
Investor relations: Andrea Matthews
investors@astriatx.com Media: Elizabeth Higgins
media@astriatx.com
Astria Therapeutics (NASDAQ:ATXS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Astria Therapeutics (NASDAQ:ATXS)
Historical Stock Chart
From Mar 2023 to Mar 2024